Health Care Down as Moderna Shares Slide -- Health Care Roundup
Health-care companies fell as a lackluster earnings season for the sector wound down. Shares of vaccine maker Moderna fell after it warned it expects to report a hefty quarterly loss, as recapturing ...
Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...
Moderna remains the most shorted stock among S&P 500 healthcare stocks in the first month of 2025
Short interest in S&P 500 healthcare stocks edged higher in January. Discover industry insights, top shorted stocks like Moderna, & trends by sector.
Moderna price target lowered to $25 from $35 at Wolfe Research
Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna outlines $1.5B-$2.5B 2025 revenue target with focus on 10 product approvals
Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...